American bio-pharmaceutical company Millennium is the latest high profile company to join Britest Limited.
A wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Millennium is exclusively focused on oncology to improve the treatment of cancer around the world. In addition to its launched products Velcade® and MEPACT®, the company has more than 15 drug candidates in its pipeline targeting a range of cancers.
Established in 1993 as a genomic company, Millennium Pharmaceuticals Inc. was acquired by the Takeda Pharmaceutical Company Limited - one of Japan’s largest pharmaceutical companies - in March 2008.
In joining Britest, Millennium joins 22 other global industry and academic leaders who share a common collaborative ethos to derive value from process innovation and whole process understanding.
Millennium will gain access to - and be trained in the use of - Britest’s range of proprietary tools and methodologies focused on primary and secondary pharmaceutical manufacture. The company will also work with Britest to develop ‘whole process understanding’ as a mechanism for achieving Quality by Design – a critical aspect of pharmaceutical manufacture.
Millennium’s decision to join Britest follows the successful demonstration of Britest’s tools and methodologies for physical processing at the companies facility in Cambridge, MA. in 2010
Sue Fleet, Britest CEO said: “I am delighted to welcome Millennium as our latest company member. As a bio-pharmaceutical company with many products in development, I look forward to supporting Michelle Sparks and Mike Bourland and their colleagues in developing detailed process understanding in order to bring these vital cancer treatments to market as quickly as possible.”